Treatment of psychotic symptoms in patients with dementia. Risperidone and olanzapine related deaths - What now?;Todesfälle unter risperidon und olanzapin - Was nun? Behandlung psychotischer symptome bei demenzpatienten

PsychoNeuro

Volumn 30, Issue 6, 2004, Pages 314-316

  Jüptner, Markus ^a   Gastpar, Markus ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; HALOPERIDOL; OLANZAPINE; RISPERIDONE;

APATHY; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; DEATH; DEMENTIA; DEPRESSION; DYSPHORIA; HALLUCINATION; HUMAN; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SHORT SURVEY; SYMPTOM;

EID: 3142751101     PISSN: 16119991     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-829992     Document Type: Short Survey

References (13)

1. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64: 134-143
2. Chan WC, Lam LC, Choy CN, Leung VP, Li SW, Chiu HF. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 2002; 16: 1156-1162
3. Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. Dement Geriatr Cogn Disord 2002; 13: 67-73
4. De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, Young CA, Lehman DL, Breier A.; Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2004; 19: 115-126
5. Fisher R, Blair M, Shedletsky R, Lundell A, Napoliello M, Steinberg S. An open dose finding study of melperone in treatment of agitation and irritability associated with dementia. Can J Psychiatry 1983; 28: 193-196
6. Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161: 1113-1115
7. Hope T, Keene J, Fairburn CG, Jacoby R, McShane R. Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease. Br J Psychiatry 1999; 174: 39-44
8. Kozma CM, Engelhart LM, Long S, Greenspan A, Mahmoud R, Baser O. Absence of increased relative stroke risk in elderly dementia patients treated with risperidone versus other antipsychotics. ICGP Programm book, www.icgp.org/ICGP_2003_ program_Book.pdf 73, 2003
9. Lawlor B. Managing behavioural and psychological symptoms in dementia. Br J Psychiatry 2002; 181: 463-465
10. Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev 2002; 2:
11. Padberg F, Karger A, Hampel H, Haupt M. Pharmakotherapie II: Behandlung nichtkognitiver Symptome. In: Hampel H, Padberg F, Möller H-J (eds.). Alzheimer Demenz. Klinische Verläufe, diagnostische Möglichkeiten, moderne Therapiestrategien. Wissenschaftliche Vertagsgesellschaft, Stuttgart, 2003; 377-391
12. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000; 57: 968-976
13. Wynn ZJ, Cummings JL. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dement Geriatr Cogn Disord 2004; 17: 100-108